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ABSTRACT  
 
  
 This is cross-sectional descriptive study conducted on patient with 
myocardial infactional period April – October 2003 in the CCU in 
Alshaab and Omdurman teaching hospitals to investigate diabetes as a 
risk Factor.  
Two-hundered patient were included in this study, 47% were 
diabetic, 44% of them had high level of FBS and 43% with high level of 
2 hours post prandial. 
In addition there was coexisting other risk Factors such as 
hypertension 33% hypercholesterolemia 22%, hypertriglyceriedaemia 
23% and smoking 49%. In hypertensive patients the systolic blood 
pressure was more than 160mmHg in 42.2% while diastolic blood 
pressure were more than 110mmHg in 15.2%. Also this study showed 
that MI is more common in male 67% than female 33%. 
This study concluded that diabetes is major risk factor for 
myocardial infraction in Sudanese patient.  
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 ﻣﻠﺨﺺ ﺍﻷﻃﺮﻭﺣﺔ
  
  
ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻭﺼﻔﻴﺔ ﻓﻲ ﺍﻟﻔﺘﺭﺓ ﻤﺎ ﺒﻴﻥ ﺃﺒﺭﻴل ﺤﺘﻰ   
ﺩ ﺸﻤﻠﺕ ﻭﻗ، ﻟﻠﺫﺒﺤﺔ ﺍﻟﻘﻠﺒﻴﺔ   ﻟﺩﺭﺍﺴﺔ ﺍﻟﺴﻜﺭﻱ ﻜﻌﺎﻤل ﻤﺴﺒﺏ3002ﺇﻜﺘﻭﺒﺭ 
 ﻤﺭﻴﺽ ﺒﻘﺴﻡ ﺍﻟﻌﻨﺎﻴﺔ ﺍﻟﻤﺭﻜﺯﺓ ﺒﻤﺴﺘﺸﻔﻰ ﺍﻟﺸﻌﺏ ﻭﺃﻡ ﺩﺭﻤﺎﻥ 002ﺍﻟﺩﺭﺍﺴﺔ 
ﻤﻥ ﻫﺅﻻﺀ ﺍﻟﻤﺭﻀﻰ ﻤﺼﺎﺒﻭﻥ ﺒﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﺒﻺﻀﺎﻓﺔ ﻟﻌﻭﺍﻤل % 74ﺍﻟﺘﻌﻠﻴﻤﻴﻴﻥ 
ﻭﺍﻟﺘﺩﺨﻴﻥ % 22 ﻭﺇﺭﺘﻔﺎﻉ ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل –%33ﺃﺨﺭﻯ ﻜﺈﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ 
، ﻜﻤﺎ ﺃﻥ ﻓﻲ ﻤﺭﻀﻰ ﺍﻟﻀﻐﻁ ﻜﺎﻥ ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻻﻨﻘﺒﺎﻀﻲ ﺃﻜﺜﺭ ﻤﻥ % 1.94
ﺒﻴﻨﻤﺎ ﻜﺎﻥ ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻻﻨﺒﺴﺎﻁﻲ ﺃﻜﺜﺭ ﻤﻥ % 2.24ﻤﻠﻡ ﺯﺌﺒﻘﻲ ﻓﻲ 061
ﺒﺎﻹﻀﺎﻓﺔ ﻟﺫﻟﻙ ﺃﻭﻀﺤﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ ﺍﻟﺫﺒﺤﺔ % 2.51ﻤﻠﻡ ﺯﺌﺒﻘﻲ ﻓﻲ 011
  .ﺍﻟﻘﻠﺒﻴﺔ ﺃﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ ﻓﻲ ﺍﻟﺫﻜﻭﺭ
ﺨﻠﺼﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺇﻟﻰ ﺃﻥ ﺍﻟﺴﻜﺭﻱ ﻋﺎﻤل ﺭﺌﻴﺴﻲ ﻤﺴﺒﺏ   
  .  ﻟﻠﺫﺒﺤﺔ ﺍﻟﻘﻠﺒﻴﺔ ﻓﻲ ﻤﺭﻀﻰ ﺍﻟﺴﻭﺩﺍﻥ
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ABBREVIATIONS 
AMI Acute Myocardial Infraction 
CAC Coronary Artery Disease 
CCU Coronary Care Unit 
CDC Centre for Disease Control  
CHD Coronary Heart Disease 
CVD Cardiovascular Disease 
DCCT Diabetes Control and complication Trial  
HBA Hemoglobin A 
HBAc1 Hemoglobin Ac1 
HDL High Density Lipoprotein  
LDL Low Density Lipoprotein 
MI Myocardial Infarction 
Mo Month 
S.O.B Shortness of Breath 
UKPDS United Kingdom Prospective Diabetes Study 
VLDL Very Low Density Lipoprotein  
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INTRODUCTION & LITERATURE REVIEW 
 
Acute myocardial infarction (AMI) is the rapid development of 
myocardial necrosis caused by a critical imbalance between the oxygen 
supply and demand of the myocardium. This usually results from plaque 
rupture with thrombus formation in a coronary vessel, resulting in an 
acute reduction of blood supply to a portion of the myocardium(1). 
The most common cause of acute myocardial infarction is 
narrowing of the epicardial blood vessels due to atheromatous plaques. 
Plaque rupture with subsequent exposure of the basement membrane 
results in platelet aggregation, thrombus formation, fibrin accumulation, 
hemorrhage into the plaque, and varying degrees of vasospasm. This can 
result in partial or complete occlusion of the vessel and subsequent 
myocardial ischemia. Total occlusion of the vessel for more than 4-6 
hours result in irreversible myocardial necrosis, but reperfusion within 
this period can salvage the myocardium and reduce morbidity and 
mortality. Most of the damage occurs in the first 2-3 hours. Restoration of 
flow within the first 4-5 hours is associated with salvage of the heart 
muscle, but the salvage is greater if flow is restored in the first 1-2 hours.  
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A major determinant of death and illness is the size of the infarct. 
Increasing the oxygen supply to the involved site of blockage by 
coronary reperfusion (angioplasty, stent, and atherectomy) is more 
effective in salvaging the myocardium than decreasing oxygen demand(1). 
Diabetes is well recognized as independent risk factor for cardiovascular 
disease in men and women CVD is up to four times more common in 
people with diabetes than those without and 50% of diabetic people have 
evidence of CVD at the time of their diagnosis. In addition, the risk of 
myocardial infarction and death from coronary disease is the same for 
diabetic people without history of MI as for nondiabetic people with 
history of MI. Moreover, post infarction mortality is significantly higher 
in people with diabetes than in those with out. It is estimated that between 
75% and 80% of diabetes related death is attributed to macrovascular 
complication of the disease, primarily CVD cerebrovascular disease and 
peripheral vascular disease (2). 
Prevalence of diabetes varies to some degree by sex and ethnicity. 
Among people who are 20 years of age or older, diabetes occur somewhat 
more commonly in white men than in white women (4.7% of woman 
9.7% of man). 
Remarkably, the mortality rate among African- American men and 
women is at least twice that of whites. (2) Asian has very high incidence of 
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Diabetes and I.H.D. The pathogenesis of CVD associated with diabetes is 
not yet fully under stood. However, because atherosclerotic 
macrovascular complications occur at an earlier age and with greater 
severity in people with diabetes, it is likely that its pathogenesis is 
directly influenced by the diabetic state (2). 
Long-term exposure to elevated glucose levels alone can contribute to the 
endothelial cell dysfunction observed in diabetes. Increasing evidence 
suggests that endothelial dysfunction may play a central role in 
development of atherosclerosis. Endothelial dysfunction is characterized 
by inhibited vasodilatation increased vascular smooth muscle 
proliferation, increased thrombogenesis, and proatherogenic cellular 
processes. Abnormal endothelium dependent vasodilatation also occurs in 
the microcirculation of diabetic patients, where it may contribute to 
ischemia and its sequelae. In addition to accelerated atherosclerosis, 
endothelial dysfunction has been linked with increased thrombosis, 
hypertension, and dyslipidemia, all of which contribute to pathogenesis of 
vascular disease in diabetes (2). 
Hyperglycemia might contribute to atherosclerosis in type 2 diabetes in a 
number of other ways. For example, hyperglycemia causes glycosylation 
of proteins in a process that induces cross-linking of collagen and other 
extra cellular matrix proteins in the arterial wall (2). 
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The end products of glycation modify low-density lipoprotein (L.D.L) 
cholesterol, prolonging its half-life and producing changes in the artery 
rendering it more susceptible to atherosclerosis. Among other proposed 
biochemical pathway in the pathogenesis of diabetic macro vascular 
disease is glucose induced activation of protein kinase C isoforms and 
increased intracellurar oxidative stress (2). 
Hyperglycemia is a well-established independent risk factor for CVD, 
and intensive treatment of hyperglycemia has been shown to prevent or 
slow the progression of long-term micro vascular complications of type 2 
diabetes. 
According to the Center for Disease Control and Prevention [CDC], 97% 
of adults with diabetes have one or more lipid abnormalities. The central 
characteristic dyslipidaemia in-patient with type 2 diabetes is an elevated 
triglyceride level, particularly triglyceride-rich VLDL levels and 
decreased HDL cholesterol levels. In diabetic patients, the concentration 
of LDL cholesterol is usually not significantly different from that seen in 
nondiabetic individuals. However, patients with type 2 diabetes typically 
have a preponderance of smaller, denser, oxidized LDL particles, which 
may increase atherogenicity, even if the absolute concentration of LDL 
cholesterol is not elevated (2). 
Most recently, results of the Strong Heart Study indicate that LDL 
cholesterol is an independent predictor of CVD with diabetes, along with 
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age, albuminuria, fibrinogen, HDL cholesterol (inverse predictor), and 
percent body fat (inverse predictor). Starting with LDL levels as low as 
70mg/dl, every 10mg/dl increase in LDL cholesterol was associated with 
a 12% increase in risk of CVD. This finding is supported by results of 
prospective, long-term clinical trials in which reduction of LDL levels 
was associated with a significantly reduced risk of cardiovascular events 
in both diabetic and nondiabetic participants (2). 
In addition to lipid abnormalities and hyperglycemia, which are 
independently atherogenic, hypertension is also known to be a major risk 
factor for CVD in all populations. Although a causal connection between 
insulin resistance and hypertension has been debated, the evidence to 
support this possibility is increasing. Together, hypertension and overt 
diabetes substantially and synergistically increase the risk of CVD, as 
well as of microvascular complication. 
In addition to being at risk of microvascular disease, patients with 
diabetes are at very high risk of macrovascular disease, particularly CVD. 
Because diabetic patients without previous MI have as high a risk of MI 
as nondiabetic patients with previous MI, all diabetic patients should be 
treated aggressively for the prevention of CVD(2). 
Cardiovascular complications (e.g. Coronary artery disease [CAD], 
stroke, peripheral vascular disease, cardiomyopathy, congestive heart 
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failure) are the leading cause of morbidity and mortality related to 
diabetes mellitus. 
Complications of atheresclerosis are responsible for about 80% of deaths 
in diabetic patients and 75% of hospitalizations for diabetic 
complications. In a 7 year study conducted in Finland, the absolute risk 
for major Cardiovascular events in patients who had type 2 diabetes with 
out known cardiovascular disease was 20.2% compared with 18.8% in 
matched non diabetic patients who had established cardiovascular 
disease. Even before the development of hyperglycemia, persons with 
impaired glucose tolerance have an elevated risk of macrovascular 
disease. 
Fifty percent of patients have evidence of cardiovascular disease at the 
time of diagnosis of type2 diabetes (7). 
Although mortality due to cardiovascular disease has continued to decline 
in non-diabetic population in the past 25 years, it has remained steady or 
has increased in the diabetic population. Persons with diabetes also have 
higher risk of death before and after infarction as well as an increased 
incidence of congestive heart failure. As the number of diabetic patient's 
increase, so too does the implication on public health (7). 
In north Sweden in Monica area, a study was done to investigate diabetes 
as risk factor for acute myocardial infarction from population perspective 
in region with high cardiovascular disease risk. All patients with acute 
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myocardial infarction aged 35-64 years were included in a total of 3031 
patients between 1984 and 1993. The results showed that the prevalence 
in diabetes was 5%in men and 4.4% in women. The relative (RR) risk in 
diabetic men was 2.9%, 95% confidence interval (1) 2.6-3.4, and in 
diabetic women, RR 5.0, CI 3.9-6.3. The risk for re-infarction was about 
twice as large in patients with diabetes as with patients without diabetes. 
In both sexes the over all 28 day case fatality (CF) was significantly 
higher in diabetic compared to non-diabetic subjects. When compared to 
non-diabetic population, the overall mortality from myocardial infarction 
in the diabetic population was 4 times higher among men and seven times 
higher among women. The population attributable risk [PAR], acrude 
estimate of all acute myocardial infractions ascribed to diabetes, was 11% 
in men and 17% in women. The study concluded that diabetes increases 
the risk for A.M.I, attack rate, incidence, case fatality, recurrence and 
mortality and is an important contributor to all AMIs in middle aged 
people (3). 
Diabetes can be considered a vascular disease because it causes both 
microvascular complications (e.g.: Nephropathy, retinopathy) and 
macrovascular complications. Tight glycemic control has been shown to 
prevent long term microvascular complication in patients with type 1 
diabetes in the Diabetes Control and Complication Trial (DCCT) and in 
those with type 2 diabetes in the United kingdom Prospective Diabetes 
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Study (UKPDS).However, glycemic control did not reduce the incidence 
of cardiovascular events in either study. 
This result in the DCCT may have been due, in part, to the young age of 
the subjects and the short duration of the study. Nevertheless, early 
recognition of major risk factors for cardiovascular disease in addition to 
hyperglycemia should be emphasized in the primary care setting (7). 
The American Association now recognized diabetes as a major 
cardiovascular risk factor. The other major cardiovascular risk factors 
(Smoking, dyslipidaemia, and hypertension act) as independent 
contributors to cardiovascular disease in diabetic patients. The vascular 
affects of smoking have been well documented (7). 
Risk factors in Diabetes for MI: 
Hyperglycemia: 
Results from the DCCT and the UKPDS showed that(7) intensive 
glycemic control (i.e. hemoglobin A1c [Hb A1c <7%]) significantly 
reduced the risk of microvascular events. In contrast, epidemiological 
studies have shown a clear association between glucose intolerance and 
coronary artery disease, as well as a direct relationship between elevated 
HBA1c values and risk of CAD. A large-scale meta-regression analysis 
involving 95,783 diabetic patients (94% men) during a l2.4-year period 
showed that nondiabetic level of fasting and postprandial hyperglycemia 
appeared to be associated with cardiovascular disease (7). 
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The diagnostic parameter (e.g. Fasting glucose<l26mg/dl and treatment 
goals (e.g. Hb A1c <7%) in diabetes have been selected to prevent 
microvascular complications and, thus, may not be adequate to prevent 
macrovascular disease. 
Prevention of cardiovascular disease may require glycemic control to 
"normal" levels (i.e., Hb A1c < 6%) or a longer period of time as well as 
control of postprandial blood glucose levels (7). 
In the UKPOS, treatment of hyperglycemia with insulin, sulfonylureas, or 
metaformin hydrochloride provided comparable reduction in 
microvascular complications in relation to reduction in HbAlc values. 
Only intensive treatment with metformin as first line therapy of a subset 
of obese patients achieved a positive effect on rates of macrovascular 
events. Intensive treatment with insulin or sulfonylureas (with raise 
insulin levels) did not increase the rate of myocardial infarction, thus, 
even though hyperinsulinemia is a risk factor for cardiovascular disease, 
treatment with this agent did not increase the risk of cardiovascular 
mortality.The thiozolidinediones may offer additional benefits by directly 
improving insulin sensitivity as well as glycemic control before its 
withdrawal from the market; troglitazone (Rezulin) was shown to have 
reduced intimamedial wall thickness in carotid arteries independent of 
glycemic control (7). 
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Under current standards, treatment of hyperglycemia alone clearly does 
not   prevent   macrovascular   disease  in  patients  with   type  2 diabetes,  
although the impact of glycemic control on other variable (e.g. 
Dyslipidaemia with improvement in VLDL triglyceride level) can not be 
ignored, assessment of all risk factors and aggressive treatment to achieve 
goal are critical to reduce cardiovascular risk in diabetic patients(7). 
Dyslipidaemia: 
Result from the study, which was done in China Medical (4) University, 
to assess the risk factor of myocardial infarction and polymorphism gene 
Apoliprotein (APOE) genotype among MI patients and their siblings 
showed the medians of total cholesterol, (TC), triglyceride (TG), low 
density lipoprotein-c (LDL-C), in MI group and sibling group  were 
higher than those in the control group with statistical significance. Body 
mass index (BMI) 25Kg/m, cigarette > 10/dl TC>5.2 mmol/L, TG 
>2.26mmol/L, LDL-C>3.4mmol/L, TC/HDL-C>5mmol/L and fasting 
blood glucose (FBG»5.6mmol/L were risk factor for MI, HDL -c>. 
9mmol/L were a protective factor for MI. Among the here genotypes of 
APOE, E3/3 was the commonest one. However, no significant difference 
was found in the distribution frequencies of these 3 genotypes, levels of 
serum lipid and lipoprotein, and Tc/HDL-c. Among the patients the 
number of allele E4 carrier was nearly twice the number of the non-allele 
E4carrier. The conclusion is that dyslipidaemia is an important risk factor 
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for MI, and polymorphism of APOE may be an indirect risk factor of 
coronary heart disease genetically. Addition to that, serum total 
cholesterol remains an important risk factor for myocardial infarction in 
men and women aged 70 years and older, whilst HDL cholesterol at older 
age remains important in women only (4). 
The Scandinavian Simvastatin Survival Study (4s) showed 42% reduction 
in coronary heart disease events in diabetic patients with known high low 
density lipoprotein-c (LDL-C) levels with simvastatin therapy (mean also 
dose 27mg/d with LDL-c reduction approximately 35%. Less degree 
reduction have been shown in other secondary prevention studies in-
patients treated with pravastatin with mild to moderate elevation at 
baseline. 
The diabetic subgroup in the Veterans Administration High Density 
Lipoprotein (HDL) Intervention Trial (V A-HIT) showed approximately 
22% reduction events in patients with diabetes and known CHD when 
HDL -C was increased by approximately 6% by gemfibrozil. 
Hypertension: 
Hypertension and diabetes are both independent risk factors for 
cardiovascular disease. When they coexist, they are synergistic in this 
effect. Hypertension in the diabetic patient markedly heightens the risk of 
end stage renal disease, coronary artery disease, stroke peripheral 
vascular disease, and diabetic retinopathy(6). 
 22
Importantly, control of blood glucose alone is not enough to optimally 
reduce the incidence of diabetes-related mortality or myocardial 
infarction in the hypertensive diabetic patient treatment of coexistent 
hypertension is also essential. Indeed, drug therapy is recommended for 
any diabetic patient whose blood pressure is higher than 130/85mmHg(6). 
Hypertension increases the risk of coronary heart disease, left ventricular 
hypertrophy, congestive heart failure, and peripheral vascular disease in 
patients with diabetes. Prospective trials in hypertensive patients with 
type 2 diabetes have shown that blood pressure control is an extremely 
effective and important prevention therapy, regardless of class of 
medication used (7). 
Between 1976 and 1991, morbidity and mortality from hypertension 
declined significantly because of increased awareness, more consistent 
treatment, and better control. Unfortunately, that trend has been reversed 
since 1991. The most recent figures of the national health and nutrition 
education survey (NHANES III, phase 2) showed that awareness, 
treatment, and control of hypertension have declined(5). 
According to the National High Blood Pressure Education Program 
working group report on hypertension in diabetes, hypertension is twice 
as common in people who have diabetes as in these who do not. The 
problem is particularly pervasive among women and specific ethnic 
groups. Almost twice as many African Americans as whites and three 
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times Mexican Americans as non-Hispanic whites have coexistent 
diabetes and hypertension (5). 
Although hypertension occurs more often in patients with type 1 than 
with type 2 diabetes mellitus, after adjustment for age, the prevalence of 
hypertension in type 2 diabetic patients increases with age. About 90% of 
patients who have a dual diagnosis of diabetes and hypertension have 
type2 diabetes (5). 
Consequently, patients with type 2 diabetes represent the majority of 
hypertensive patients (5). 
Pathophysiology: 
The diabetic patients have increased vascular reactivity to various 
vasoconstrictors and increased total exchangeable body sodium as sub 
group of patients are "sat-sensitive", which mean they have heightened 
vasoconstrictive response to a given sodium load. These patients have 
poor prognosis with respect to cardiovascular events. 
Hyperinsulinemia and insulin resistance can contribute to hypertension, 
as can hyperlipidaemia and coagulation abnormalities. A strong family 
history of diabetes and essential hypertension appears to identify type 1 
diabetic patients in whom renal disease and hypertension are likely to 
develop(5). 
Cardiovascular disease risk in patients with hypertension alone is a 
multifactorial problem complicated by the presence or absence of 
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diabetes, as well as other risk factors (e.g. Smoking, dyslipidaemia, age > 
60 years, male sex, being postmenopausal family history of 
cardiovascular disease)(5). 
The Joint National Committee (JNC VI) report empirically classifies 
hypertensive patients into one of three risk groups, based on thesis 
components of cardiovascular risk (table1-1) (5). 
Table (1-1): Risk stratification and treatment of hypertension  
Blood pressure 
(mmHg) 
Risk group A Risk group B Risk group C 
High normal 
(130-139/85-89) 
Life style 
modification 
Life style 
modification 
Drug therapy 
Stage 1 (140-
159/90-99) 
Life style 
modification up 
to (12 mo) 
Life style 
modification (up 
to 6 mo) 
Drug therapy 
Stage 2 and 3 > 
160 > 100 
Drug therapy Drug therapy Drug therapy 
 
The JNCVI classification depends on the presence or absence of target 
organ damage or clinical cardiovascular disease (e.g. Left ventricular 
hypetrophy, previous coronary revascularization, and heart failure). Risk 
group A comprises patients who do not have any other risk factor or 
target organ damage or clinical cardiovascular disease (5). 
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Risk B includes patients with at least one risk factor (excluding diabetes) 
but with out target organ damage or clinical cardiovascular disease. 
Risk group c comprises patients with target organ damage or clinical 
cardiovascular disease, with or with out other risk factors. This group 
includes all patients with diabetes, regardless of the presence or absence 
of other risk factors or of target organ damage or clinical cardiovascular 
disease. 
Drug therapy is the recommended strategy for any diabetic patient in any 
stage of hypertension. 
Because of the variability in blood pressure and the propensity for 
autonomic dysfunction and orthstatic hypotension in-patients with 
diabetes, blood pressure should be measured in the supine, Sitting, and 
standing positions. Ambulatory monitoring may also be useful (5). 
The JNCVI classifies optimal blood pressure for cardiovascular risk to be 
at or below 120/80 mm Hg in adults aged 18 years or older. Normal 
blood pressure is classified as at or below 130/85 mm Hg, and data from 
clinical trials indicate that this is a realistic goal for patients with diabetes. 
More over, the data also indicate that diabetic patients benefit more than 
the population at large from a decrease in blood pressure (5). 
Result from the Hypertension Optimal Treatment (HOT) study showed 
that the risk of major cardiovascular events in the patient population as 
whole was not affected by lowering the diastolic blood pressure, while a 
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51% reduction in study events was seen in diabetic patients who were 
randomly assigned to a target diastolic blood pressure group with a goal 
at below 80 mm Hg (5). 
United Kingdom Prospective Diabetes Study (UKPDS) involving 
hypertensive patients with type2 diabetes, 758 patients were assigned to 
tight control of blood pressure and 390 patients to less tight control. 
Blood pressure was significantly lower in the group assigned tight control 
(144/82mm Hg), compared with the other group (154/87 mmHg). 
Even though the difference in diastolic blood pressure between the two 
groups was only 5mmHg, tight control resulted in significantly greater 
reduction in risk of diabetes related end points, including deaths from 
diabetes and strokes and development of microvascular complications, 
than did less tight control. Although reducing diastolic blood pressure is 
clearly important, a recent study of elderly, type 2 diabetes patients with 
isolated systolic hypertension (systolic blood pressure > = 160mmHg, 
diastolic pressure < = 90mmHg) also indicated that reduction of systolic 
blood pressure reduce relative and absolute risk of cardiovascular events. 
In fact, anti-hypertensive therapy to lower systolic pressure was 
associated with reduced relative and absolute risks of nonfatal and fatal 
cardiovascular events (both coronary and cerebral) in diabetic as well as 
non-diabetic patients, compared with placebo-treated patients. Further 
more, the reduction in absolute risk was consistently greater for the 
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treated hypertensive diabetic patients than for treated nondiabetic  
patients (7). 
The Hypertension Optimal Treatment Trial evaluated the effect of 
calcium channel blocking agent on hypertensive patients (8% of who 
were diabetic). 
Significant reduction in major cardiovascular events (prevention of 1.5 
myocardial infarction per 1.000 patients treated for 1 year and 2.5 
myocardial infarction per 1.000 patients -years in diabetic patients) was 
seen when diastolic blood pressure was reduced to a mean of 82.6-mm 
Hg. In study of isolated systolic hypertension in patients with type 2 
diabetes in Europe (s-E trial), risk reduction in cardiovascular end points 
ranged from 35% to 76% in the diabetic patients, and no excess risk of 
major cardiovascular events was seen in the diabetic group compared 
with the nondiabetic group(7). 
In the Heart Outcomes Prevention Evaluation study, Angiotensin 
converting enzyme (ACE) inhibitors have potential renal protective effect 
and a macrovascular benefit in addition to effect on blood pressure. 
However, ACE inhibitors may worsen renal function in-patients with 
bilateral renal artery stenosis and may cause hyper- kalemia, conditions 
for which patients with type 2 diabetes at increased risk. Use of thiazide 
diuretics and beta-blockers in diabetic patients has been controversial, 
because these agents can cause worsening in lipid or glucose control as 
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well as blunting of hypoglycemic symptoms. However, risk of such 
effects need not preclude use of beta-blockers in diabetic patients who 
have myocardial infarction (7). 
The American Diabetes Association and the Sixth Report of the Joint 
National Committee recommended a target blood pressure of less than 
130 /85 mm Hg where the National kidney Foundation urges a more 
aggressive treatment goal of 130/80 mmHg. 
Independent of the agent used, aggressive blood pressure control should 
be a high patients priority in diabetic (7). 
Table (1-2): Lipoprotein risk adult patients levels and treatment 
goals in with diabetes:  
 
 Low Risk Level, 
mg/dl (mmol/L) 
Optiml level, 
mg/dl (mmol/L) 
Border line High 
Lipoprotein      
LDL 
cholesterol  
100 < 100  
(2.60) 
< 100-129 
(2.60-334) 
130 
(3.35) 
HDL 
cholesterol  
>45 >45 
(1.15) 
33-45  
(0.85-1.15) 
<35 
(0.90) 
Triglycerides <200 <200 
(2.26) 
200-399 
(2.26-450) 
400 
(4.52) 
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Lifestyle  
Social history 
Family history  
Physical activity 
Serum lipids and lipoprotein levels 
Cigarette smoking  
Diet, nutrition, alcohol ingestion 
Physical examination (renal status, cardiovascular disease, retinopathy) 
Blood pressure  
Glycemic status  
Comorbid diseases  
 
(8) Adapted with permission from Grundy SM, Benjamin IJ, Burke 
GL, Chait A, Eckel RH, Howard BV, et al. 
Diabetes and cardiovascular disease: 
A statement for healthcare professional’s from the American Heart 
Association. 
Circulation 1999;  
100: 1134-46 (Published erratum appears in circulation 2000; 101: 1629-31). 
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Smoking: 
The link between smoking and heart disease has been well described in 
population all over the world. Twenty five Years follow up of Seven 
COUNTRIES study, (16 cohorts of men aged 40 to 59 at enrolment in the 
USA, Finland, the Netherlands, Italy, Croatia, Serbia, Greece and Japan), 
reported a dose- dependent increase in risk of death. After 25 years, 
57.7% of parsons smoking 30 cigarettes per day had died compared to 
only 36.3% of non -smoking. Additional long-term data came from a 40 
year follow up to British physicians which noted that excess mortality 
from cardiovascular disease was two times higher among smokers 
compared to non- smokers but that ratio was even more extreme during 
middle age(9). The data for men and women differ somewhat but recent 
work underlines the importance of smoking as a cause of myocardial 
infarction in both men and women. 
As an example, in a Norwegian study, rates of myocardial infraction were 
4.6 times in men than in women but rates among women who smoked 
were six times higher than non-smokers and rates among men, three times 
higher than among nonsmokers. Danish investigators concluded that 
women may be more sensitive to tobacco as risk of myocardial infarction 
as both current smoking and total tobacco exposure were consistently 
higher in women than men, and higher for both groups regarding 
myocardial infraction rates among non-smokers (9). 
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While there are certain genetic conditions that cause atherosclerosis, 
studies of twin pairs in which one smokes and other dose not demonstrate 
that smoking can increase the size of plaques in the carotid arteries by 
over three fold. A larger plaque means the vessel is narrower, thus 
increasing risk of stroke, in the case of the carotid arteries, or ischemic 
heart disease in case of coronary arteries (9). 
In an increasing number of health systems, patients are offered expensive 
therapies such as coronary bypass surgery or angioplasty in an effort to 
open or bypass vessels that have became so narrow that they are unable to 
supply sufficient oxygen to the heart. American data report that after an 
average four and a half years of follow-up, people who continued to 
smoke after angioplasty had a 76% increased risk of death compared to 
non-smokers and a 44% higher risk of death compared to those who quit 
smoking(9). 
Moreover, risks of myocardial infarction were similar in non-smokers and 
those who were successful in quitting smoking after surgery (9). 
Smoking and Diabetes: 
As documented in the American Diabetes Association's technical 
review "Smoking and Diabetes" [1], a large body of evidence from 
epidemiological, case-control, and cohort studies provides convincing 
documentation of the causal link between cigarette smoking and health 
risks. Cigarette smoking is the leading avoidable cause of mortality in the 
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U.S., accounting for [sim] 434,000 deaths each year. Cigarette smoking 
accounts for one out of every five deaths in the U.S. and is the most 
important modifiable cause of premature death. Cigarettes provide the 
delivery system for nicotine, an addictive substance related to various 
pharmacological, biochemical, and psychological processes that interact 
to support a compulsive pattern of drug use(20). 
Much of the prior work documenting the impact of smoking on health did 
not discuss separately results on subsets of individuals with diabetes, 
suggesting the identified risks are at least equivalent to those found in the 
general population. Other studies of individuals with diabetes consistently 
found a heightened risk of morbidity and premature death associated with 
the development of macrovascular complications among smokers. The 
cardiovascular burden of diabetes, especially in combination with 
smoking, has not been effectively communicated to both people with 
diabetes and health care providers. Smoking is also related to the 
premature development of microvascular complications of diabetes and 
may have a role in the development of type 2-diabetes. 
General smoking prevalence has decreased over the past 10 years because 
of extensive public health efforts, which include making the population 
aware of the health hazards of active and passive smoking, 
implementation of smoking cessation interventions, and policy changes. 
However, 26-28% of American adults continue to smoke, with variations 
 33
reported by ethnic and sociodemographic groups. These figures mirror 
the prevalence of tobacco use among individuals with diabetes. It appears 
adolescents may initiate smoking after being diagnosed with diabetes and 
that the prevalence of tobacco use decreases with disease duration. 
Effectiveness of smoking cessation counseling: Smoking cessation is one 
of the few interventions that can safely and cost-effectively be 
recommended for all patients and has been identified as a gold standard 
against which other preventive behaviors should be evaluated. A number 
of large randomized clinical trials have demonstrated the efficacy and 
cost-effectiveness of certain forms of provider and behavioral counseling 
in changing smoking behavior of primary care and hospitalized patients. 
This work, combined with the more limited studies specific to individuals 
with diabetes, suggests that smoking cessation counseling is effective in 
reducing tobacco use in this high-risk group (20). 
Although many large-scale well-controlled outcome studies have 
included patients with diabetes, seldom have results been reported 
separately for diabetes versus other participants. Special issues that affect 
successful abstinence have been identified in these studies and include 
weight management and depression. 
Post cessation weight gain may be an impediment to smoking cessation, 
especially among women or other people concerned with weight 
management. The presence of comorbid psychiatric conditions such as 
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depression is associated with prevalence of smoking and heightened 
relapse after quitting. Though not reported separately, these issues are 
expected to be at least equally relevant for diabetic patients as for general 
patients (20). 
Relation of cigarette smoking to myocardial infarction in young 
women: 
To examine the relation between myocardial infarction and cigarette 
smoking in young women, the smoking habits of women under the age of 
50 who had survived a recent myocardial infarction were investigated. 
They had not been using oral contraceptives, and other identifiable risk 
factors were excluded. Among 55 such women and 220 control matched 
for age and area of residence, the proportions of cigarette smokers were 
89% and 55% respectively (P less than 0.001). A dose-response relation 
was evident; among women 35 or more cigarettes per day the rate of 
myocardial infraction was estimated to be some 2 folds higher than 
among those who had never smoked. This study demonstrates that 
cigarette smoking is a factor for myocardial infarction in young women 
who are otherwise apparently healthy (10). 
Secondary prevention: 
This prospective study on one hundred and nineteen cigarette smokers 
(90men, 29 women) who survived their first myocardial infarction for 
one month were followed for five years or until their death if earlier. The 
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age corrected mortality rate of men who continued to smoke cigarettes 
was 2.2 times the age corrected mortality rate of those who stopped 
smoking after their infarct. The women who continued to smoke had 2.4 
times the age corrected mortality of those who stopped smoking. The age 
corrected mortality rates for the combined group of men and women 
show that those who stopped smoking after their infraction have 55% of 
the mortality of those who continued to smoke (P less than 0.05). These 
results suggest that smoking is not merely "risk factor" for myocardial 
infarction but is also a causal factor whose effects can be avoided by both 
men and women after an initial myocardial infraction (11). 
Effect of smoking cessation on mortality after myocardial infarction: 
Meta-analysis of cohort studies: 
Result of several cohort studies suggests that smoking cessation after 
myocardial infarction is associated with a significant decrease in 
mortality (12). 
Oral contraceptives and myocardial infraction: 
Shortly after oral contraceptives become widely available, a 1963 report 
identified them as a risk factor for myocardial infraction. Subsequent 
studies showed that women who took oral contraceptives and were heavy 
smokers were at 30 time's greater risk for myocardial infarction than were 
women with neither risk factor. Partly in response to these adverse 
effects, oral contraceptives with lower doses of estrogen and varying 
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types of progestogens were developed. These newer contraceptives, 
containing second generation (mainly levonorgestrel) appeared to be an 
improvement over the earlier ones, but risks of arterial disease and 
myocardial infarction remained (13). 
Oral contraceptive containing third generation progestogens (gestodene 
or desogestrel) has recently been marked. There is conflicting evidence 
regarding the cardiovascular risks of these newer agents. Some studies 
showed no significant difference in the myocardial infarction between 
women reporting prior use of second-generation oral contraceptives and 
those reporting use of third generation products. 
Smoking remains the most important risk factor for myocardial infraction 
in women aged 18 to 49. Tanis and colleagues whom conduct a case -
control study using the knowledge that third generation products are 
widely used in the netherlands, found that women who did not take oral 
contraceptives but who smoked had an adjusted risk for myocardial 
infarction of 7.9 (9504.9-12.9) compared with women who did not 
smoke(13). 
Control and prevention: 
Despite the findings of Tanis and his colleagues, the overall evidence 
makes it unclear whether third-generation oral contraceptives pose less of 
a risk for myocardial infarction than their second-generation counterparts. 
However, whatever the patient's choice, she should be advised that the 
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risk of myocardial infarction increases with age, that smoking remains a 
very strong risk factor, and that smoking and taking oral contraceptives 
may put them at very high risk. As with patients of any age demonstrable 
gains in risk reduction are possible by paying attention to treating 
hypertension and lowering elevated cholesterol levels (3). 
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OBJECTIVE 
 
It has been observed that diabetes mellitus is very common in Sudanese 
patients presenting with acute myocardial infarction. 
This study was carried out to investigate the frequency of diabetes as a 
risk factor for myocardial infarction in Sudanese patients compared to 
some other countries and to look into the status of glycaemic control by 
such patients. 
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PATIENTS AND METHODS 
Study design and area:  
A descriptive cross-sectional study conducted on all patients with 
myocardial infarction in the CCU in Alshaab and Omdurman Teaching 
Hospitals.  
Study period: 
During the period, first April – October 2003. 
Study population: 
This study was conducted on 200 patients who were admitted to 
the CCU with myocardial infarction, and studied by the author herself.  
Methodology: 
A questionnaire consisting of age, sex, duration of diabetes, type of 
medication, other risk factors – presenting symptoms, physical 
examination was designed, and investigation including, ECG, cardiac 
enzymes, lipid profile, Fasting Blood Sugar (F.B.S), 2 hours post prandial 
(2hpp) [Normal <140, 4mg/dl], chest x-ray, echocardiography, blood urea 
and electrolyte were all done.  
Data analyses: 
Computer using SPSS (Statistical Package for Social Sciences) 
analyzed the data. 
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RESULTS 
This study was conducted on 200 patients with myocardial 
infarction to investigate diabetes as a risk factor. Ninety-four patients 
(47%) were diabetic as shown in (Table 1). 
The age distribution of the patients ranged between (30-85)            
(Table 2) with minimum of 32 and maximum of 80 years. 
Male : female distribution, is 67% : 33% respectively (Figure 1). 
Figure (2) shows medications, dietary control, oral hypoglycemic 
agent, and insulin therapy. 
The risk factors are shown in (Tables 3, 4, 5 & 6), with frequency 
of smoking in 49% of patients, and a duration of more than 10 years in 
65.3% of them. Hypertension occurred in 33% with a duration of more 
than 10 years in 48.5%, hypertriglyceridaemia in 23% and 
hypercholestraemia in 22%. High-density lipoprotein was low in one-
percent only (Table 7), while low density lipoprotein was found in 10%, 
as shown in (Table 8). Alcohol consumption in 24%, with duration of 
more than 10 years (62%). 
Distribution of presenting symptoms and signs, 85% presented 
with chest pain, 69% with sweating, 46% with palpitation, 20% with 
signs of heart failure, 8% with syncope and 2% with signs of 
hyperlipidaemia (Figure 3 & 4). 
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ECG showed 94% of patients had evidence of acute MI, 7% had 
arrhythmia and 9% had other abnormal finding (Figure 5). 
Cardiac enzyme was abnormally high. CPK was high in 82%, LDH 
in 82%, and SGOT in 73% (Figure 6). 
Abnormal chest x-ray was found in 37% while echo was found to 
be abnormal in 98%. 
Fasting blood glucose was high in 44% where postprandial was 
high in 43% (normal values 126mg/dl, 140.4mg/dl respectively). 
The blood urea was high in 14%. The systolic blood pressure was 
high in 42.2% of patients (> 160 mmHg) and the diastolic pressure was 
high in 15.2% (110 mmHg).  
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Table (1): 
Showing frequency of diabetes among the study group 
Case distribution No. % 
Not diabetic  106 53.0 
Diabetic  94 47.0 
Total  200 100.0 
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Table (2): 
Showing age distribution  
Age group No. % 
30 – 39 years  8 4.0 
40 – 49 years  34 17.0 
50 – 59 years  50 25.0 
60 – 69 years  68 34.0 
70 – 79 years  32 16.0 
80 – 89 years  8 4.0 
Total  200 100.0 
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Table (3): 
Other risk factor (Hypertension) 
Hypertensive  No. % 
Yes 66 33.0 
No  134 67.0 
Total  200 100.0 
 
 
Table (4): 
Other risk factor (Smoking) 
Smoker  No. % 
Yes  98 49.0 
No  102 51.0 
Total  200 100.0 
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Table (5): 
Investigation (Triglyceride)  
Triglyceride  No. % 
Normal  154 77.0 
Abnormal  46 23.0 
Total  200 100.0 
 
 
Table (6): 
Investigation (Cholesterol) 
Cholesterol  No. % 
Normal  156 78.0 
Abnormal  44 22.0 
Total  200 100.0 
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Table (7): 
Investigation (LDL) 
LDL No. % 
Normal  180 90.0 
Abnormal  20 10.0 
Total  200 100.0 
 
 
Table (8): 
Investigation (HDL) 
HDL No. % 
Normal  198 99.0 
Abnormal  2 1.0 
Total  200 100.0 
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Table (9): 
Range of systolic blood pressure (mm/hg) 
Blood pressure  No. % 
80 – 89  4 2.0 
90 – 99 20 10.0 
100 – 109  12 6.0 
110 – 119 42 21.0 
120 – 129 24 12.0 
130 – 139  30 15.0 
140 – 149 28 14.0 
150 – 159 12 6.0 
160 – 169 6 3.0 
170 – 179 6 3.0 
180 – 189 10 5.0 
200 – 209 2 1.0 
240 – 249 2 1.0 
Irricordable  2 1.0 
Total  200 100.0 
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Table (10): 
Range of diastolic blood pressure (mm/hg) 
Blood pressure  No. % 
60 – 69  34 17.0 
70 – 79 36 18.0 
80 – 89 56 28.0 
90 – 99  50 25.0 
100 – 109  12 6.0 
110 – 119  2 1.0 
120 – 129  4 2.0 
130 – 139 2 1.0 
140 – 149  2 1.0 
Irricordable  2 1.0 
Total  200 100.0 
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Table (11): 
Showing the levels of LDL in studied population  
LDL mg/dl No. % 
400 – 499 7 35.0 
500  13 65.0 
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DISCUSSION 
This descriptive cross-sectional study was carried out to investigate 
diabetes as a risk factor for myocardial infarction in Sudanese patients. 
A total of 200 patients were investigated, 47% of patients were 
found to be diabetic. This is the highest figure in comparison with other 
risk factor a part from smoking, which accounted for 49% of patients, 
while hypertension represented 33%, hypertriglycerdaemia 23%, and 
hypercholesteraemia 22%. 
This figure of 47% is high even in comparison to other studies, 
which were, done elsewhere to investigate diabetes as a risk factor for 
myocardial infarction. In north Sweden in Monica area such study was 
done from population studied in region with high cardiovascular disease. 
The population attributable risk (PAR), a crude estimate of all acute 
myocardial infarction ascribed to diabetes, was 11% in men and 17% in 
women a total of twenty eight percent(3). 
In EUROASPIRE I and II surveys patients with CHD aged 70 
years or younger were interviewed and examined at least 6 months after 
 63
hospitalization for a revascularization procedure or acute myocardial or 
ischaemia.  
In EUROASPIRE I and II 18% and 20% of CHD patients 
respectively had been previously diagnosed with diabetes. Fasting 
glucose screening raised the prevalence of diabetes in EUROASPIRE II 
to 28%.  
A comparison of both studies showed that for diabetic and non-
diabetic patients the prevalence of smoking had increased somewhat and 
that the prevalence of obesity had increased clearly. There was no 
improvement in blood pressure control, but cholesterol control had 
improved, mainly explained by the increased use of lipid-lowering drugs. 
These European surveys showed that a high risk factor status was more 
adverse in diabetic patient’s(18). 
In Kuwait a study to compare the in hospital mortality after acute 
myocardial infarction (AMI) among diabetic versus non-diabetic patients 
was carried out.  
19% of 149 patients were diabetic. History of diabetes mellitus 
(DM) was found to be significantly associated with in hospital mortality 
after AMI (odds ratio : 1.9, 95% CI : 1.2 – 3.0). 
This study concluded that the risk of in hospital mortality after 
AMI is almost doubled among diabetic patient’s(19). 
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In Perth, Australia retrospective study was conducted to assess the 
relationship between clinical course after AMI and diabetes treatment. 
Short (28 days) and long-term survival and complication in diabetic and 
non-diabetic patients were compared, 12.9% were diabetic. Mortality at 
28 days was 12 and 28.1% for non-diabetic and diabetic patients 
respectively(17). 
In Diabetes Control and Complication Trial and United Kingdom 
Prospective Diabetes Study, it was proved that tight glycemic control 
prevent long term microvascular complications in patients with type l and 
type II diabetes(7), so the high percentage of diabetes in our patients with 
myocardial infarction, might be contributed to poorglycaemie control. 
This is shown by the high fasting blood sugar in 93.62% pt, and the high 
two hours postprandial in 91.49%pt. Kumar and Clark (15) had mentioned 
that there is a progressive secretary failure of beta cells in type2 diabetes. 
The diabetes slowly worsens over years and those patients, who are 
initially adequately controlled with diet, or diet and tablet, will need 
gradual increases of their treatment over time. For most patients tablets 
will eventually fail to achieve adequate metabolic control and change to 
insulin treatment will become necessary. The most wide spread error in 
management at this stage is procrastination; the patient whose control is 
inadequate on oral therapy should start insulin without undue delay (15). 
However in this study the majority of patients were on oral hypoglycemic 
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agent (63.8%), while only 27.1% were on insulin therapy. It is well 
known that ischemic heart disease is more common in type2 diabetes. 
Accordingly, this might be the cause of high percentage of cases of M.I in 
the studied population, or it might be due to wrong treatment with tablets 
instead of insulin, or due to poor patient's compliance or to the unwise 
follow up. Two third of this group were diabetic for more than ten years 
which increases the chance for long-term complications. 54% percent of 
the patients were over 60year of age. 
It is reported that a graded relation ship has been demonstrated 
between the duration and degree of sustained hyperglycemia, however 
caused and at whatever age it develops, and the risk of vascular 
disease(16). 
This means, the longer the duration of diabetes the more is prone to 
long term complications due to diabetes and other coexisting risk factors 
e.g. hypertension and dyslipidaemia. Thus comparing our study for 
incidence of diabetes in cases of AMI with studies mentioned above 
shows that diabetes is very common among Sudanese patients presenting 
with M.I. 
Screening of the studied population showed high levels of serum 
cholesterol (22%), triglyceride (23%), low-density lipoprotein (10%), 
while high-density lipoprotein was only present in one percent. Indeed 
these high levels were attributable at least partially, to uncontrolled 
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diabetes in the study group, which causes some degree of dyslipidaemia. 
In addition, the great majority of patients were not on anti-dyslipidaemic 
therapy. Anti-dyslipidaemic drugs leads to reduction in coronary heart 
disease. This was proved in diabetic patients in the Scandinavian 
Simvastatin Survival Study (4S)(7). 
This dyslipidaemia possibly is related to dietary factor, because 
Sudanese peoples tend to consume meat, which is great source of 
exogenous fat. 
The striking thing in this data was that the high-density lipoprotein 
was low in only one percent of patients, and it is unclear whether it was 
due to small studied population, laboratory errors or other unknown 
factors. 
33% of patients in the study group were hypertensive: 42.4 % of 
them had systolic pressure of more than 160mmHg and 15.2 % had 
diastolic pressure more than 110mmHg at presentation reflecting 
uncontrolled severe hypertension. This might be due to poor compliance; 
also most patients tend to stop medication if they were informed that they 
have normal reading in follow up clinic. Also poor dietary measures were 
additional factor. 
The coexistent hypertension in diabetes (7) markedly heightens the 
risk of coronary artery disease, so it is essential to treat high blood 
pressure. The prospective trials in hypertensive patients with type 2 
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diabetes have shown that blood pressure control is an extremely effective 
and important prevention therapy, regardless to class of medication.                     
A result from Hypertension Optimal Treatment (HOT) study showed that 
the risk of major cardiovascular event in the patient population as whole 
was not affected by lowering the diastolic blood pressure, while 51% 
reduction was seen in diabetic patients who were randomly assigned to a 
target diastolic blood pressure group with a goal at below 80 mm Hg (5). 
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CONCLUSION  
• This study concluded that diabetes is major risk factor for 
myocardial infarction, representing highest percentage among other 
risk factors.  
• Tight glycemic control in type 1 and type 2 diabetes prevents long-
term microvascular complications.  
• Dyslipidaemia should be detected early and treated aggressively, 
especially in diabetic patients.  
• Optimal blood pressure control with accurate antihypertensive 
drugs will lead to average reduction in cardiovascular events in 
diabetic patient.  
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RECOMMENDATIONS 
• Good glycemic control is important to prevent myocardial 
infarction in diabetic patient. 
• Optimal blood pressure control in diabetic patient will reduce the 
occurrence of myocardial infarction in diabetic patient.  
• Detection of dyslipidaemia in diabetic patient and aggressive 
therapy will lead to average reduction in the percentage of diabetes 
as risk factor for MI. 
• Diabetic patient should be encouraged to stop smoking. 
• Diabetic patient should be advised to perform certain physical 
activities with ideal dietitian and nutritional program.  
• Physical examination including renal status, cardiovascular disease 
and retinopathy should be carried out in every follow-up clinic. 
• Accurate decisions concerning the type of medication whether to 
be oral or insulin therapy.  
• Diabetic patient with positive family history of MI should be under 
especial concern.  
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Diabetes as Risk Factor for 
Myocardial Infarction in Sudanese  
Questionnaire 
 
 Patient Name:  
   Age            Yr. 
  
 Gender:    M         F 
         Tribe: 
 Residence: 
 Origin: 
 Occupation: 
 Duration of Diabetes: 
 Type of Medication:      insulin                       Oral 
  
 Other Risk Factors: 
    - Hypertension      
           
    Duration           ↓ 10                   ↑10  
     
    - Smoking  
 
    Duration         ↓ 10                   ↑10 
 
    - Hyperlipidemia 
 
- Alcohol  
 
Duration           ↓ 10                   ↑10   
 
Others 
   Symptoms : 
- Chest Pain  
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        -Palpitations  
 
         -Syncope 
 
Examination:  
         - Pulse           Beats/ min  
 
        - BP                      MMHg 
 
- Sign of Heart Failure   
 
- Sign of Hyperlipidemia     
 
Investigations:  
   Normal             Abnormal  
      - ECG        MI Arr Oth 
   
 Normal    High 
 - Cardiac Enzymes       CPK  LDH   SGOT 
 
 
-Triglyceride   
 
-Cholesterol 
 
-HDL 
 
-VLDL  
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   Normal              Abnormal 
- CXR 
 
-ECHO 
 
-FBS 
 
-Post Prandial  
 
-B.rea 
 
-S.Creatinine  
 
-K 
 
-Na  
         
 
                     
          
             
 
 
